10x Genomics (MEX:TXG) Change In Payables And Accrued Expense : MXN-134 Mil (TTM As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is 10x Genomics Change In Payables And Accrued Expense?

10x Genomics's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2025 was MXN36 Mil. It means 10x Genomics's Accounts Payable & Accrued Expense increased by MXN36 Mil from Dec. 2024 to Mar. 2025 .

10x Genomics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was MXN-336 Mil. It means 10x Genomics's Accounts Payable & Accrued Expense declined by MXN336 Mil from Dec. 2023 to Dec. 2024 .

10x Genomics Change In Payables And Accrued Expense Historical Data

The historical data trend for 10x Genomics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

10x Genomics Change In Payables And Accrued Expense Chart

10x Genomics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

-126.08

-696.70

179.25

378.25

-335.57

10x Genomics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-134.28	30.58	-13.17	-187.68	36.46

10x Genomics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-134 Mil.

10x Genomics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of 10x Genomics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

10x Genomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » 10x Genomics Inc (MEX:TXG) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

TXG:USA 0A88:UK 1KJ:Germany

Address

6230 Stoneridge Mall Road, Pleasanton, CA, USA, 94588

Website

https://www.10xgenomics.com

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).